Antibacterial · Silver · CAS 7440-22-4
Colloidal Silver
Ag
Colloidal silver is heavily marketed as a 'natural antibiotic,' but has no confirmed efficacy in oral-care RCTs and carries argyria risk with prolonged use.
QDRO position
We avoid itNo RCTs confirming efficacy in oral care; argyria risk and potential nanoparticle cytotoxicity. QDRO does not use it.
Effective concentration
N/A (no oral-care RCT data)
Typical on market: 10–25 ppm (in products)
What it is
Colloidal silver is a suspension of silver nanoparticles (Ag⁰) or Ag⁺ ions in water. Silver has antimicrobial properties known since antiquity, and this fact is exploited by the marketing of "colloidal silver" products. In oral care (rinses, sprays, toothpastes) it is positioned as a "natural antibiotic without chemicals."
How it supposedly works
The Ag⁺ ion is genuinely toxic to bacteria: it binds sulfhydryl groups on proteins, blocks respiratory chain enzymes, and disrupts DNA replication. This mechanism is well characterised in vitro. The problem is not the mechanism itself, but the gap between laboratory concentrations and real-world oral exposure — and the absence of human evidence.
Efficacy — where is the data?
Antimicrobial activity of silver nanoparticles has been demonstrated in test tubes. However, there are no large randomised controlled trials confirming clinically meaningful reductions in plaque, gingivitis, or caries from colloidal silver oral-care use in humans. Fung & Bowen (1996) concluded as early as the 1990s that the benefits of silver products are not supported by adequate clinical evidence, while the risks are well documented.
Unlike chlorhexidine, cetylpyridinium chloride, or zinc gluconate — no regulatory body (FDA, EFSA, or equivalent) has approved colloidal silver as an active antibacterial agent for oral care.
Safety — real risks
Argyria — an irreversible blue-grey discolouration of skin and mucous membranes caused by chronic silver accumulation in tissues. Cases of argyria have been reported in long-term users of ingested colloidal silver. Oral rinsing followed by partial swallowing creates chronic low-level exposure.
Nanoparticle cytotoxicity: Asharani et al. (2009) demonstrated cytotoxicity and genotoxicity of silver nanoparticles in human cells in vitro.
FDA (1999) issued a final rule stating that colloidal silver is "not generally recognised as safe and effective" for any oral ingestion indication.
Role in the QDRO formula
QDRO does not use colloidal silver in any product. This is a core brand position: every active ingredient must have a clinical evidence base. For antibacterial action, QDRO uses ingredients with confirmed efficacy — zinc gluconate, CPC, copper gluconate — without the risks associated with metal nanoparticles.